I thought it was a great update.
Starting to really kick goals on testing with a big revenue increase coming for FY 24.
I understand we need about $20 mil revenue to be operationally break even. That could come in the next 2 years in that the major international distribution partners we have are only now just starting to kick off.
On the Therapeutics side we are moving forward well on several fronts and in partnership with some very big players.
$32 mil in the Bank is plenty of cash to see us through to a very positive outcome.
The company is definitely travelling under the radar ( but for how much longer )
Ann: Q4 FY23 Quarterly Investor Presentation, page-4
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $78.37M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $22.11K | 122.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12556 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 64647 | 3 |
View Market Depth
| Last trade - 15.50pm 02/10/2024 (20 minute delay) ? |
| MAP (ASX) Chart |